Asset Details
Do you wish to reserve the book?
Traumatic brain injury, changes in plasma amyloid, tau, and neurodegenerative biomarkers, and dementia risk
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Traumatic brain injury, changes in plasma amyloid, tau, and neurodegenerative biomarkers, and dementia risk
Do you wish to request the book?
Traumatic brain injury, changes in plasma amyloid, tau, and neurodegenerative biomarkers, and dementia risk
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Traumatic brain injury, changes in plasma amyloid, tau, and neurodegenerative biomarkers, and dementia risk
2025
Overview
INTRODUCTION Long‐term trajectories of plasma biomarkers in relation to incident traumatic brain injury (TBI) and whether TBI modifies associations of biomarkers with dementia risk are unknown. METHODS One thousand fifty Atherosclerosis Risk in Communities (ARIC) study participants without prior TBI had amyloid beta (Aβ42/Aβ40), phosphorylated‐tau181 (pTau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) measured from plasma collected in 1993 to 1995, 2011 to 2013, and 2016 to 2019. Linear mixed‐effects models estimated biomarker trajectories associated with TBI and Cox proportional hazards models determined if TBI modified associations of biomarkers with incident dementia through December 31, 2020. RESULTS After the median time of incident TBI, Aβ42/Aβ40 levels remained lower for 9.3 years, and pTau181, NfL, and GFAP remained elevated for 8.5, >13.8, and 12.7 years, respectively. There was evidence of additive interaction by TBI in associations of log2NfL with incident dementia (p = 0.024). DISCUSSION TBI alters trajectories of plasma biomarkers of neurodegeneration for approximately a decade after the injury and modifies associations of NfL with dementia risk. Highlights Our findings provide evidence that TBI fundamentally alters trajectories of plasma biomarkers of AD‐related pathology, neuronal degeneration, and astrogliosis for approximately a decade after the injury. Further, our findings also suggest that an incident TBI event adds to and interacts with ongoing neurodegenerative processes to increase the risk of later life dementia. These results suggest that the pathologic processes underlying post‐TBI dementia are heterogeneous, that individuals with preclinical changes in neurodegenerative biomarkers may be more susceptible to TBI (i.e., that associations are bidirectional), or a combination thereof.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Amyloid beta-Peptides - blood
/ Brain
/ Brain Injuries, Traumatic - blood
/ Brain Injuries, Traumatic - complications
/ Brain Injuries, Traumatic - epidemiology
/ Codes
/ Dementia
/ Female
/ Glial Fibrillary Acidic Protein - blood
/ Humans
/ Injuries
/ Male
/ Neurofilament Proteins - blood
/ Plasma
/ Risk
/ TBI
/ Trauma
